Proficio Capital Partners LLC Purchases New Stake in Bruker Co. (NASDAQ:BRKR)

Proficio Capital Partners LLC acquired a new stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,376 shares of the medical research company's stock, valued at approximately $608,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. True Wealth Design LLC increased its holdings in shares of Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after buying an additional 510 shares during the last quarter. Eagle Bay Advisors LLC lifted its holdings in Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after buying an additional 674 shares during the period. UMB Bank n.a. lifted its stake in Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after acquiring an additional 248 shares during the period. GAMMA Investing LLC boosted its stake in shares of Bruker by 47.5% during the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after purchasing an additional 412 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Bruker by 13.5% in the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company's stock valued at $127,000 after purchasing an additional 257 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Remove Ads

Bruker Trading Up 0.6 %

NASDAQ:BRKR traded up $0.27 on Wednesday, reaching $43.51. The company's stock had a trading volume of 1,863,901 shares, compared to its average volume of 1,322,012. The stock has a 50 day moving average price of $51.15 and a 200 day moving average price of $57.25. Bruker Co. has a 12-month low of $42.70 and a 12-month high of $94.52. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The firm has a market cap of $6.60 billion, a price-to-earnings ratio of 57.25, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, equities analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.46%. Bruker's payout ratio is currently 26.32%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BRKR shares. Stifel Nicolaus reduced their price target on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a report on Monday, February 24th. Bank of America upped their price target on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. UBS Group initiated coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price target for the company. Finally, Barclays lowered their target price on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $70.50.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.